翰宇药业与KuCoin达成战略合作，共探中国创新药RWA项目先河
8月4日，翰宇药业与全球领先的数字资产平台KuCoin正式签署战略合作意向书，双方拟共同探索在香港共同推进中国内地首个以“创新药研发未来收益权”为底层资产的RWA（Real World Asset）代币化试点项目。
本次合作聚焦于以翰宇药业自主研发、具有高技术壁垒的创新药及仿制药管线为基础，探索符合中国大陆及香港虚拟资产监管框架的合规化RWA发行路径，旨在为生物医药领域引入具备可复制性的新型融资与价值发现机制。
根据协议，翰宇药业将以其在GLP-1类多肽重磅药物领域的技术积累与研发管线为基础资产，KuCoin则将发挥其在区块链技术、RWA全流程解决方案和全球合规资源方面的优势，为该项目提供链上映射、资产通证化、交易撮合、收益分配等一体化支持。
双方战略协同主要体现在三方面：
资本协同：依托KuCoin平台超4100万用户的全球网络，为翰宇药业拓展海外合规资本通道；
技术协同：实现关键研发里程碑与链上收益数据的透明映射，增强投资者信任；
品牌协同：树立“中国创新、全球标准”的国际形象，共探中国医药行业RWA合规化样板项目。
翰宇药业表示：“我们希望通过本次合作，在保障数据安全和法律合规的前提下，打通一条‘科技-医药-金融’融合的创新通路，推动研发资产的价值前置化释放，并激发全球资本对中国原创新药的关注与参与。”
KuCoin表示：“翰宇药业代表了中国生物医药领域的硬科技力量。我们希望以本项目为起点，探索更多高质量资产的RWA实践，助力产业转型升级。”
本次合作不仅是翰宇药业在全球化布局中的关键一步，更有望为整个医药行业在资本与技术融合方面提供新的范式与想象力。
关于翰宇药业
一家专注于创新药物研发、生产与销售的A股上市的国家级高新技术企业，深耕多肽药物20余年，拥有覆盖全球主流多肽靶点的完整制剂管线，包括但不限于GLP-1R/GIPR/GCGR三重受体激动剂原创新药、瑞他鲁肽、替尔泊肽、司美格鲁肽、利拉鲁肽等全球重磅多肽ANDA制剂，累计授权国内外专利近500项，为GLP-1日制剂利拉鲁肽ANDA全球首家在美国FDA获批上市企业，产品已进入欧美规范市场。
关于KuCoin
成立于2017年，为全球数字经济发展中具有先驱地位且广受认可的平台，依托尖端的区块链基础设施、流动性解决方案和卓越的用户体验构建坚实根基，为全球用户提供全方位数字资产解决方案，现有全球200多个国家和地区的4100万用户，并获福布斯2025年度最佳加密货币交易所。平台具备全流程RWA发行技术储备：资产确权、收益数据化、资产上链、交易安全、机构级托管、链上收益分配、流动性提供、提供交易平台等，并承诺将尽最大努力取得香港监管机构要求的全部许可。
Hybio Pharma and KuCoin Join Forces to Pioneer China’s First RWA Pilot in Innovative Drug Development
On August 4, 2025, Hybio Pharma (SZSE: 300199) officially entered into a strategic partnership with KuCoin, a globally recognized digital asset platform. The two parties will co-launch China’s first Real World Asset (RWA) pilot project based on the future revenue rights of innovative and high-barrier generic drugs, with Hong Kong as the initial launch site.
Hybio, a leading Chinese peptide pharmaceutical company, specializes in the development and commercialization of peptide-based therapeutics and holds a robust GLP-1 portfolio with FDA-approved products in the U.S.
KuCoin, with over 41 million global users, brings to the table full-stack RWA infrastructure, covering asset tokenization, on-chain revenue mapping, secure custody, and regulatory compliance.
This groundbreaking collaboration aims to unlock the value of intangible R&D assets through digital tokenization, allowing for real-time price discovery and flexible funding structures. The issuance will follow Hong Kong’s latest virtual asset regulatory framework, setting a new precedent for compliant RWA models in the pharmaceutical industry.
The partnership reflects a shared vision to drive innovation at the intersection of science, technology, and finance — and positions Hybio as a global frontrunner in bridging pharmaceutical R&D with next-generation capital markets.
About Hybio Pharma
Hybio Pharma (SZSE: 300199) is a listed pharmaceutical company that has focused on peptide drugs for more than 20 years. Dedicated to research, development, manufacturing, and commercialization of innovative medicines. With more than 20 years of experience in peptide therapeutics, the company has built a comprehensive portfolio that spans virtually all major global peptide targets. Its pipeline includes first-in-class triple-receptor agonists (GLP-1R/GIPR/GCGR) and blockbuster peptide ANDA formulations such as retatrutide, tirzepatide, semaglutide, and liraglutide. Hybio holds nearly 500 domestic and international patents and was the first company worldwide to receive FDA approval for a independent generic liraglutide injection. Its products are now marketed in regulated markets across North America and Europe.
About KuCoin
Founded in 2017, KuCoin is a globally recognized pioneer in the digital economy. Built on cutting-edge blockchain infrastructure, deep liquidity solutions, and an industry-leading user experience, KuCoin delivers end-to-end digital-asset services to more than 41 million users in over 200 countries and regions. In 2025, Forbes named KuCoin the Best Crypto Exchange. The platform possesses full-cycle RWA issuance capabilities—asset validation, revenue digitization, on-chain tokenization, transaction security, institutional-grade custody, on-chain revenue distribution, liquidity provision, and exchange listing, and is committed to securing all licenses required by Hong Kong regulators.
